Navigation Links
Phase 3 Open-Label Study Comparing Tapentadol Extended Release Tablets to Oxycodone Controlled Release Tablets Published by Pain Practice
Date:7/19/2010

of using monoamine oxidase inhibitors (MAOIs) due to potential additive effects on norepinephrine levels, which may result in adverse cardiovascular events.

Respiratory depression is the primary risk of mu-opioid agonists. Respiratory depression occurs more frequently in elderly or debilitated patients and in those suffering from conditions accompanied by hypoxia, hypercapnia, or upper airway obstruction, in whom even moderate therapeutic doses may significantly decrease pulmonary ventilation. NUCYNTA® should be administered with caution to the elderly, debilitated patients, and patients with conditions accompanied by hypoxia, hypercapnia or decreased respiratory reserve such as: asthma, chronic obstructive pulmonary disease or cor pulmonale, severe obesity, sleep apnea syndrome, myxedema, kyphoscoliosis, CNS depression, or coma. In such patients, even usual therapeutic doses of NUCYNTA® may increase airway resistance and decrease respiratory drive to the point of apnea. Alternative non-mu-opioid agonist analgesics should be considered and NUCYNTA® should be employed only under careful medical supervision at the lowest effective dose in such patients. If respiratory depression occurs, it should be treated as any mu-opioid agonist-induced respiratory depression.

Patients receiving other mu-opioid agonist analgesics, general anesthetics, phenothiazines, other tranquilizers, sedatives, hypnotics, or other CNS depressants (including alcohol) concomitantly with NUCYNTA® may exhibit additive CNS depression. Interactive effects resulting in respiratory depression, hypotension, profound sedation, coma or death may result if these drugs are taken in combination with NUCYNTA®. When such combined therapy is contemplated, a dose reduction of one or both agents should be considered.

Opioid analgesics can raise cerebrospinal fluid pressure as a result of respi
'/>"/>

SOURCE PriCara
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... analysis of Centers for Medicare and Medicaid Services, (CMS) ... percent of seniors chose lower-cost preferred pharmacy plans that ... The findings were released by Drug Channels . ... of Medicare Part D," said Pharmaceutical Care Management Association ...
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Immune Therapeutics, Inc. ... Biotechnology, Inc. for the compounding, packaging and distributing of its ... the United States . ... of compounding naltrexone tablets in various strengths for individual patients ...
(Date:1/23/2015)... 23, 2015  Now available for sale, The Armor1 Ankle ... prevents ankle sprains by cushioning the ankle from an ... around the outside of any shoe type and allows ... still offering protection against sprains. With customers in physical ...
Breaking Medicine Technology:New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2
... 2011 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: ... of medical devices worldwide, announced today an agreement to ... Technical Development Co. Ltd. The terms of the transaction ... Mindray,s financial statements. Founded in 2004 and ...
... Nev., Feb. 28, 2011 PDL ... financial results for the fourth quarter and full year ended ... were $345.0 million, compared to $318.2 million in 2009.  Excluding ... royalty revenues for 2010 increased 30 percent over 2009.  For ...
Cached Medicine Technology:Mindray Medical to Acquire a Controlling Stake in Shenke Medical 2Mindray Medical to Acquire a Controlling Stake in Shenke Medical 3Mindray Medical to Acquire a Controlling Stake in Shenke Medical 4PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results 2PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results 3PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results 4PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results 5PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results 6PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results 7PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results 8PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results 9PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results 10
(Date:1/22/2015)... Deer Path of Huntley -- a BMA affordable assisted ... 3 p.m. to 4 p.m. on Feb. 13. , The community, ... adults with physical disabilities between the ages of 22 and 64. ... and sweetheart-themed karaoke. , For more information about the event or ...
(Date:1/22/2015)... LunaDress, with its top dressmaking technologies, has ... the business is showing its latest designs of wedding dresses ... to the company’s CEO, all the fresh new products are ... discounts, up to 80% off. All the clothes from LunaDress ...
(Date:1/22/2015)... Gabe’s Chemo Duck Program is pleased to announce the release ... for kids with cancer. The Chemo Duck App, available on iTunes ... enjoyable games to help children of all ages living with cancer ... keep kids entertained, educated and at ease while waiting for clinic ...
(Date:1/22/2015)... 2015 The Incredible Bulk is a revolutionary ... increase lean muscle by up to 30lbs in less than ... of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , “Our ... step-by-step, scientific diet formula that allows the body to pack ...
(Date:1/22/2015)... the premier women’s dress supplier, has recently released its ... of AngelWeddingDress.com to find more details. , Many ... a bridal party. AngelWeddingDress offers a variety of gorgeous ... wedding dresses are specially designed for 2015. , AngelWeddingDress ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2
... Breast cancer patients treated with intensity modulated radiation therapy ... a lower incidence of acute or chronic toxicities, according ... ( PRO ), the official clinical practice journal of ... constantly conducting studies to determine the most effective breast ...
... By Alan Mozes HealthDay Reporter , MONDAY, March ... procedures to standard diabetes treatments contends that surgery is more ... finding stems from two years of tracking 60 severely obese ... ages of 30 and 60. One-third of the patients were ...
... on 31 March when the ship and crew reach Lorient, ... across all the world,s major oceans to sample and investigate ... Karsenti in an editorial published today in Molecular Systems ... yet we know very little about the distribution of marine ...
... HealthDay Reporter , MONDAY, March 26 (HealthDay News) -- ... lowered LDL cholesterol levels in patients with high cholesterol ... treatment could help lower levels of "bad" cholesterol for ... the commonly prescribed cholesterol-lowering drugs known as statins. It ...
... (HealthDay News) -- Antibiotics can prolong cystic fibrosis patients, ... in their lungs, a new, small study suggests. ... not prove, that the current standard of aggressive antibiotic ... the best approach. It,s common to use antibiotics ...
... HealthDay Reporter , MONDAY, March 26 (HealthDay News) -- ... that people who eat chocolate regularly are somewhat skinnier than ... don,t prove that chowing down on chocolate will melt off ... for the modest difference in body mass, or it might ...
Cached Medicine News:Health News:IMRT reduces risk of side effects in breast cancer patients 2Health News:Weight-Loss Surgeries May Beat Standard Treatments for Diabetes 2Health News:Weight-Loss Surgeries May Beat Standard Treatments for Diabetes 3Health News:Weight-Loss Surgeries May Beat Standard Treatments for Diabetes 4Health News:TARA OCEANS completes 60,000-mile journey to map marine biodiversity 2Health News:New Injection Might Lower Tough-to-Treat Cholesterol 2Health News:New Injection Might Lower Tough-to-Treat Cholesterol 3Health News:Should Cystic Fibrosis Patients Get So Many Antibiotics? 2Health News:Does Chocolate Help You Stay Slim? 2Health News:Does Chocolate Help You Stay Slim? 3
...
Ascent Primary Knee System with cruciate retaining, posterior stabilized and constrained components...
... tricompartmental total knee prosthesis stems from many ... design and manufacturing technologies have been used ... as well as a favorable pressure distribution ... keep wear to a minimum. The inherent ...
The Natural-Knee Family is a complete range of interchangeable, anatomically-designed implants with over 14 years of proven clinical results....
Medicine Products: